Nina Chavez, MBA, FACMPE: Biosimilars and Patient Out-of-Pocket Costs

Nina Chavez, MBA, FACMPE, chief operating officer, New Mexico Oncology Hematology Consultants, Ltd, discusses the role that biosimilars have to play in reducing patients’ out-of-pocket costs in cancer care. 
November 01, 2019


You know, anything that can decrease the cost to the patient is the best thing for the patient.

We have financial counselors, we have a lot of copay cards, we have a lot of drug assistance, drug replacement. We as a practice work very hard to get therapies to the patients that they cannot afford. And so, if there's a way that these biosimilars coming into the market can not only lower the total cost of care, but they can lower the patients’ out-of-pocket and that stress and anxiety that the patient has, I think that's fantastic.

I don't know how it will play out because it's so new, and right now, like I said, they're kind of marketing like the brand; they're not that much cheaper. They don't want to disrupt [average selling price, ASP]; it's more about, “we’ll give you a contract to use all of our stuff, including our biosimilar, instead of using this other guy’s, right?”


Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.